Outcomes of case-matched injection sclerotherapy with a new agent for hemorrhoids in patients treated with or without blood thinners.
OBJECTIVE
In Japan, a new type of sclerotherapy termed ALTA (aluminum potassium sulfate and tannic acid) injection therapy has recently been introduced. The objectives of this study were to determine whether the presence or absence of antithrombotic treatment (AT) affected the efficacy rate or the occurrence of complications associated with ALTA injection sclerotherapy.


METHODS
This study was a case-matched study of 37 patients who underwent ALTA therapy to treat hemorrhoids between 2007 and 2009. Each AT patient was matched for age and degree of hemorrhoids with a control non-AT patient. In each of the subgroups, the therapeutic efficacy of ALTA therapy was evaluated by comparing an assessment completed before therapy with an assessment completed 6 months after therapy.


RESULTS
The efficacy in patients with bleeding did not differ between the two groups (P = 0.074). The efficacy in patients with prolapse was significantly lower in the AT group than in the non-AT group (P = 0.013). The two groups did not differ significantly in the occurrence of complications (P = 0.450).


CONCLUSIONS
Among patients with hemorrhoids receiving AT, ALTA injection sclerotherapy is recommended for those in whom it is difficult to discontinue AT.
Matsuda Hospital Colo-proctological Institute, 753 Irinocho, Nishi-ku, Hamamatsu, Shizuoka, 432-8061, Japan. yanotakaaki@hotmail.co.jp
T
T
Yano
T
T
Nogaki
M
M
Asano
S
S
Tanaka
K
K
Kawakami
Y
Y
Matsuda
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000534:Alum Compounds / Q000008:administration & dosage*; D016022:Case-Control Studies; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006484:Hemorrhoids / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015911:Sclerotherapy / Q000009:adverse effects / Q000379:methods*; D013634:Tannins / Q000008:administration & dosage*; D016896:Treatment Outcome; D014859:Warfarin / Q000008:administration & dosage / Q000009:adverse effects
D000534:Alum Compounds; D005343:Fibrinolytic Agents; D013634:Tannins; C041524:aluminum sulfate; D014859:Warfarin